Meeting
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Prognostic value of PD-L1+CD4+ T cells in non-small cell lung cancer (NSCLC) patients treated with a PD-1 inhibitor.
Authors
Kiriaki E. Vetsika
Laboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece
Kiriaki E. Vetsika, Despoina Aggouraki, Zacharoula Lyristi, Filippos Koinis, Vassilis Georgoulias, Athanasios Kotsakis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Biomarkers and Inflammatory Signatures,Humoral Immunity for Diagnosis and Therapy,Immune Checkpoints and Stimulatory Receptors,Modulating Innate Immunity,Therapies Targeting T cells
Sub Track
Prognostic and Predictive Markers
Citation
J Clin Oncol 35, 2017 (suppl 7S; abstract 58)
DOI
10.1200/JCO.2017.35.7_suppl.58
Abstract #
58
Poster Bd #
G1
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
First Author: Michelle Hsu
Poster
2020 ASCO Virtual Scientific Program
Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC.
First Author: Michael Rahman Shafique
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Association of an RNA signature (RS) with emergence of ICOS hi CD4 T cells and efficacy outcomes for the ICOS agonist vopratelimab (vopra) and nivolumab (nivo) in patients (pts) on the ICONIC trial.
First Author: Timothy A Yap
Poster
2019 ASCO Annual Meeting
Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were PD-L1 negative or less than 1 %.
First Author: Thierry Landre